Bold Therapeutics is a clinical-stage biopharma company based in Vancouver, British Columbia founded in 2018 to develop and commercialize BOLD-100, a first-in-class metallotherapeutic being developed for the treatment of advanced cancers.

Based on compelling preclinical and early clinical results, Bold Therapeutics is focusing its clinical development efforts on some of the most challenging indications where existing therapies are largely ineffective, resulting in a significant unmet medical need.

Our Team

Select on a team member's profile photo to learn more.

Profile Photo
E. Russell McAllister
Chief Executive Officer
Profile Photo
Jim Pankovich
Executive Vice President, Clinical Development
Profile Photo
Arthur Levine
Chief Financial Officer
Profile Photo
Carly Hastings
Operations Associate
Profile Photo
Michelle Koersen
Corporate Development Associate
Profile Photo
Michelle Jones
Senior Director, Clinical Development
Profile Photo
Malcolm Snow
Clinical Development Associate
Profile Photo
Mark Bazett, PhD
Senior Director, Preclinical Development
Profile Photo
Ashish Kumar, PhD
Senior Scientist, Preclinical Development
Profile Photo
Brian Jungmin Park
Scientist, Computational Biology
Profile Photo
Alun Rees
Senior Director, CMC
Profile Photo
Shane Harrypersad, PhD
Senior Scientist, CMC
Board Of Directors

Board Of Directors

Glenn Walthall
Chairman
E. Russell McAllister
CEO
Jim Pankovich
EVP Clinical Development
Simon Sutcliffe
Director
Hooshmand Sheshbaradaran
Director
Careers

Careers

Although Bold is not currently hiring for specific positions, we encourage exceptional candidates to contact us at [email protected].

Notification